Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T20:43:27.608Z.
Calculation as of: 2026-10-06T20:43:27.608Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a58e0fcb5c5c5211a6c4e1a8bb78ffa34e5085398ec1b7e8aba4a6f7bffe7660
PEG RATIO
N/A
Unicycive Therapeutics, Inc.
Market Cap
$112.94M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $112.94M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
